ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

By sjmartinez • August 31, 2023

Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, Wohl DA, Daar ES, Hughes MD; ACTIV-2/A5401 Study Team. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. J Infect Dis. 2023 Aug 31;228(Supplement_2):S77-S82. doi: 10.1093/infdis/jiad246. PMID: 37650231; PMCID: PMC10469341.

Tags: ACTIV-2, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, Publications

Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort

Boriek AM, Gordon J, Gwon Y, Adami A, Porszasz J, Rossiter HB, Rambod M, Chandra D, Diaz AA, Kinney GL, Make BJ, McDonald MN, Regan[...]

Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia

Cai J, Yue C, Tomassetti S. Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid[...]

Hyperlactatemia and pulmonary gas exchange at rest and during exercise: lessons from patients on metformin

Haouzi P, Stringer WW, Mccully J, Pichurko BM. Hyperlactatemia and pulmonary gas exchange at rest and during exercise: lessons from patients on metformin. Eur J[...]